University of Vermont

The University of Vermont Cancer Center

trials_mela.html

Melanoma Clinical Trials

The University of Vermont Cancer Center has many trials specifically focused on skin cancer research.

Status: Active - Recruiting

Study Title: A 2-part Phase III Randomized, Open Label, Multicenter Study of LGX818 Plus MEK162 Versus Vemurafib and LGX818 Monotherapy in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma

Purpose: This is a 2-part, randomized, open label, multi-center, parallel group, phase III study comparing the efficacy and safety of LGX818 plus MEK162 to vemurafenib and LGX818 monotherapy in patients with locally advanced unresectable or metastatic melanoma with BRAF V600 mutation.
ClinicalTrials.gov Identifier: NCT01909453
Contact: Kate Murray (802) 656-9401
Information: https://clinicaltrials.gov/ct2/show/NCT01909453?term=CMEK&rank=12
Institution Number: 14-174
Protocol Research Type: Industry Sponsored
Status: Active - Recruiting

Study Title: A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma

Purpose: The purpose of this study is to compare the effects, good and/or bad, of ipilimumab with interferon alfa-2b on you and your melanoma to find out which is better.  In this study, you will get either ipilimumab or the interferon alfa-2b. You will not get both. We plan to determine whether ipilimumab stops or delays your cancer from returning in comparison to interferon alfa-2b.
ClinicalTrials.gov Identifier: N/A
Primary/Site/Co Investigator: Steven Emmons, MD
Contact: Elizabeth Eldridge (802) 656-2178
Information: N/A
Institution Number: M12-125 ECOG-ACRIN 1609
Protocol Research Type: Cooperative Group - ECOG-ACRIN
Status: Active - Closed to Accrual

Study Title: A Phase I/II, Open Label Study of Ad-RTS-hIL-12, an Adenovirus Vector Engineered to Express hIL-12, in Combination with an Oral Activator Ligand, in Subjects with Unresectable Stage III or IV Melanoma. 

Purpose: The purpose of this study is to evaluate the safety and tolerability of intratumoral injections of INXN-2001 at a constant dose in combination with and oral drug INXN-1001 in patients who have unresectable stage III or IV melanoma.  Additional this study will be evaluating anti-tumor activity (as evidenced by reduction in the size of melanoma tumors). 
ClinicalTrials.gov Identifier: NCT01397708
Primary/Site/Co Investigator: Claire Verschraegen, MD
Contact: Kate Murray (802) 656-9401
Information: http://clinicaltrials.gov/ct2/show/NCT01397708?term=ATI001-101&rank=1
Institution Number: M13-027
Protocol Research Type: Industry Sponsored

Last modified July 10 2015 02:26 PM